South Dakota Investment Council continued to hold its position in Regulus Therapeutics Inc. (NASDAQ:RGLS) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,327,058 shares of the biopharmaceutical company’s stock at the end of the 2nd quarter. South Dakota Investment Council owned 2.50% of Regulus Therapeutics worth $1,308,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Teachers Advisors LLC raised its stake in shares of Regulus Therapeutics by 15.7% during the 4th quarter. Teachers Advisors LLC now owns 72,273 shares of the biopharmaceutical company’s stock worth $163,000 after purchasing an additional 9,804 shares in the last quarter. LMR Partners LLP purchased a new stake in shares of Regulus Therapeutics during the 2nd quarter worth about $164,000. Tudor Investment Corp ET AL raised its stake in shares of Regulus Therapeutics by 131.5% during the 1st quarter. Tudor Investment Corp ET AL now owns 108,061 shares of the biopharmaceutical company’s stock worth $178,000 after purchasing an additional 61,373 shares in the last quarter. Wedbush Securities Inc. raised its stake in shares of Regulus Therapeutics by 10.3% during the 2nd quarter. Wedbush Securities Inc. now owns 199,521 shares of the biopharmaceutical company’s stock worth $197,000 after purchasing an additional 18,600 shares in the last quarter. Finally, Wells Fargo & Company MN raised its stake in shares of Regulus Therapeutics by 13.5% during the 1st quarter. Wells Fargo & Company MN now owns 782,380 shares of the biopharmaceutical company’s stock worth $1,291,000 after purchasing an additional 93,295 shares in the last quarter. 21.93% of the stock is owned by institutional investors.

A number of research firms have recently weighed in on RGLS. Chardan Capital downgraded Regulus Therapeutics from a “buy” rating to a “neutral” rating in a research note on Wednesday, August 2nd. Needham & Company LLC reaffirmed a “hold” rating on shares of Regulus Therapeutics in a research note on Wednesday, August 2nd. Wedbush reaffirmed an “ourperform” rating and set a $4.00 price target on shares of Regulus Therapeutics in a research note on Monday, August 7th. Zacks Investment Research raised Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $1.00 price target for the company in a research note on Wednesday, July 12th. Finally, BMO Capital Markets set a $1.00 price target on Regulus Therapeutics and gave the stock a “hold” rating in a research note on Monday, June 12th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and one has assigned a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $3.58.

TRADEMARK VIOLATION WARNING: This report was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another website, it was illegally stolen and reposted in violation of United States and international trademark and copyright laws. The legal version of this report can be read at https://www.thecerbatgem.com/2017/09/13/regulus-therapeutics-inc-rgls-stake-maintained-by-south-dakota-investment-council.html.

In other news, insider Joseph P. Hagan acquired 219,780 shares of Regulus Therapeutics stock in a transaction dated Tuesday, July 25th. The stock was bought at an average cost of $0.91 per share, with a total value of $199,999.80. Following the completion of the transaction, the insider now directly owns 241,297 shares of the company’s stock, valued at $219,580.27. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Daniel R. Chevallard acquired 54,945 shares of Regulus Therapeutics stock in a transaction dated Tuesday, July 25th. The shares were purchased at an average cost of $0.91 per share, with a total value of $49,999.95. Following the completion of the transaction, the chief financial officer now directly owns 59,415 shares of the company’s stock, valued at $54,067.65. The disclosure for this purchase can be found here. Insiders have bought 549,450 shares of company stock valued at $500,000 over the last ninety days. 4.80% of the stock is owned by insiders.

Regulus Therapeutics Inc. (RGLS) opened at 1.12 on Wednesday. The company’s market capitalization is $116.24 million. Regulus Therapeutics Inc. has a 52 week low of $0.79 and a 52 week high of $3.65. The company has a 50 day moving average price of $0.98 and a 200-day moving average price of $1.23.

Regulus Therapeutics (NASDAQ:RGLS) last posted its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.10). The firm had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.02 million. Regulus Therapeutics had a negative return on equity of 173.20% and a negative net margin of 31,460.47%. On average, equities analysts anticipate that Regulus Therapeutics Inc. will post ($1.02) earnings per share for the current fiscal year.

About Regulus Therapeutics

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Want to see what other hedge funds are holding RGLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regulus Therapeutics Inc. (NASDAQ:RGLS).

Institutional Ownership by Quarter for Regulus Therapeutics (NASDAQ:RGLS)

Receive News & Stock Ratings for Regulus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics Inc. and related stocks with our FREE daily email newsletter.